- 米国企業
- DR REDDYS LABORATORIES LTD
DR REDDYS LABORATORIES LTDRDY
| 2019年
3月31日 | 2020年
3月31日 | 2021年
3月31日 | 2022年
3月31日 | 2023年
3月31日 |
|---|
| Profit (loss) | 272 | 259 | 236 | 311 | 548 |
|---|
| Tax expense, net | 53 | -19 | 125 | 115 | 186 |
|---|
| Adjustments for fair value losses (gains) | - | - | - | 4 | -11 |
|---|
| Depreciation and amortization | 176 | 165 | 175 | 156 | 154 |
|---|
| Impairment of non-current assets | 3 | 222 | 117 | 100 | 9 |
|---|
| Allowance for credit losses (on trade receivables and other advances) | - | -3 | 3 | 1 | 2 |
|---|
| Loss/(gain) on sale or de-recognition of non-current assets, net | - | - | - | -15 | 3 |
|---|
| Share of profit of equity accounted investees, net of tax | - | 7 | 7 | 9 | 5 |
|---|
| Foreign exchange (gain)/loss, net | -23 | -29 | 25 | -10 | -11 |
|---|
| Interest (income)/expense, net | - | 1 | -2 | - | -3 |
|---|
| Inventory write-down | 58 | - | - | - | 59 |
|---|
| Adjustments for share-based payments | 6 | 7 | 8 | 8 | 5 |
|---|
| Dividend income | - | - | - | - | - |
|---|
| Trade and other receivables | 26 | -165 | 28 | -224 | -70 |
|---|
| Inventories | -123 | -20 | -135 | -70 | -32 |
|---|
| Trade and other payables | 6 | 21 | 39 | 58 | - |
|---|
| Other assets and other liabilities, net | 8 | 64 | -45 | 53 | 6 |
|---|
| Cash generated from operations | 485 | 490 | 566 | 468 | 847 |
|---|
| Income tax paid, net | 70 | 94 | 78 | 98 | 130 |
|---|
| Net cash from operating activities | 415 | 396 | 488 | 370 | 716 |
|---|
| Expenditures on property, plant and equipment | 101 | 64 | 133 | 193 | 138 |
|---|
| Proceeds from sale of property, plant and equipment | 18 | 2 | 1 | 5 | 1 |
|---|
| Expenditures on other intangible assets | 8 | 17 | 39 | 58 | 92 |
|---|
| Proceeds from sale of other intangible assets | - | 3 | - | 39 | - |
|---|
| Payment for acquisition of business (Refer to Note 6 for details) | - | - | 212 | 4 | - |
|---|
| Purchase of other investments | 1,136 | 1,485 | 1,031 | 1,173 | 1,657 |
|---|
| Proceeds from sale of other investments | 1,103 | 1,482 | 1,087 | 1,025 | 1,372 |
|---|
| Interest and dividend received | 11 | 8 | 17 | 12 | 9 |
|---|
| Net cash used in investing activities | -112 | -65 | -310 | -348 | -503 |
|---|
| Proceeds from issuance of equity shares (including treasury shares) | - | - | - | - | 2 |
|---|
| Proceeds from sale/(purchase) of treasury shares | - | - | - | - | -3 |
|---|
| Cash flows from (used in) increase (decrease) in current borrowings | -219 | 56 | 93 | - | -236 |
|---|
| Proceeds from non-current borrowings | - | - | 52 | - | - |
|---|
| Payment of principal portion of lease liabilities (Refer to Note 17 for details) | - | - | - | 10 | 12 |
|---|
| Dividend paid | 58 | 52 | 57 | 55 | 61 |
|---|
| Interest paid | 23 | 21 | 18 | 18 | 23 |
|---|
| Net cash used in financing activities | -308 | -334 | -4 | -32 | -327 |
|---|
| Net (decrease)/increase in cash and cash equivalents | -5 | -3 | 174 | -9 | -114 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | 1 | - | 2 | 10 | 3 |
|---|